Rojas-Charry L, Nardi L, Methner A, Schmeier MJ (2020) Abnormalities of synaptic mitochondria in autism spectrum disorder and related neurodevelopmental disorders
[64] ARQ197 (ArQule) is a promising selective inhibitor of MET, which entered a phase 2 clinical trial in 2008
Based on these limitations, we propose that future research should focus on the following specific directions: clarifying the upstream regulation mechanism, developing more complex experimental models, and promoting the transformation of clinical to precision medicine
this page does not establish a stability window
She has received grants from AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Janssen and Sanofi-Aventis and Eli Lilly